Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity...
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026 Financing led by RA Capital...
Health In Tech Named to Newsweek’s America’s Greatest Mid-Market Companies 2026
Health In Tech recognized among the 100 highest-scoring U.S. public mid-market companies following an initial review of approximately 4,300 companies, based on financial strength, workforce performance, innovation and sustainability STUART, Fla., Sept. 9, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, announced today that it...
Abbott and Sengkang General Hospital expand partnership to advance early detection of muscle loss and support healthy aging
The expanded three-year collaboration will integrate muscle health screenings into hospital and community settings, train healthcare professionals, and increase public education Since launching in 2023, the partnership has trained nearly 300 healthcare professionals to assess muscle health and support earlier intervention SINGAPORE, Sept. 9, 2026 /PRNewswire/ -- Abbott and Sengkang...
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that the U.S. Food and Drug Administration...
Cleveland Clinic, RIKEN and IBM Team Advance to Finals for 2026 ACM Gordon Bell Prize
Joint research team modeled a 12,635-atom protein, the largest-known to be simulated using quantum computers. Breakthrough was achieved through quantum and classical methods working together, expanding quantum-centric supercomputing's potential in life sciences research. CLEVELAND and WAKO, Japan and YORKTOWN HEIGHTS, N.Y., Sept. 9, 2026 /PRNewswire/ -- A multidisciplinary team from Cleveland...
ZAGENO Earns Frost & Sullivan’s 2026 North American Life Sciences E‑Commerce Company of the Year Recognition
Honored for transforming life sciences procurement through digital innovation, automation, and a customer-first platform SAN ANTONIO, Sept. 9, 2026 /PRNewswire/ -- Frost & Sullivan has recognized ZAGENO with its 2026 North America Life Sciences E-Commerce Company of the Year Recognition for helping transform life sciences e-commerce beyond traditional online purchasing into a unified procurement orchestration platform. By serving as a...
Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation
SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Natural Field, a technology-driven nutraceutical ingredient solutions provider, announced the expansion of its NF TriSolve® branded nutraceutical solution platform into the growing sleep wellness category with the introduction of NF TriSolve® SleepRestore Complex. Expanding the NF TriSolve® Platform NF TriSolve® is Natural Field's branded nutraceutical solution...
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the...
GROWNSY Partners with Graham’s Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay
NEW YORK, Sept. 8, 2026 /PRNewswire/ -- GROWNSY, a baby care brand trusted by more than 3 million households worldwide, today announced a new long-term partnership with Graham's Foundation, a nonprofit organization dedicated to supporting parents of premature babies. The partnership will begin during NICU Awareness Month this September through GROWNSY's Tiny Steps Home campaign, which supports families navigating...
